skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization

Journal Article · · ACS Medicinal Chemistry Letters
 [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1]
  1. Merck and Co., Inc., Boston, MA (United States)
+ Show Author Affiliations

Optimization of a series of highly potent and kinome selective carbon-linked carboxamide spleen tyrosine kinase (Syk) inhibitors with favorable drug-like properties is described. A pervasive Ames liability in an analogous nitrogen-linked carboxamide series was obviated by replacement with a carbon-linked moiety. Initial efforts lacked on-target potency, likely due to strain induced between the hinge binding amide and solvent front heterocycle. Consideration of ground state and bound state energetics allowed rapid realization of improved solvent front substituents affording subnanomolar Syk potency and high kinome selectivity. These molecules were also devoid of mutagenicity risk as assessed via the Ames test using the TA97a Salmonella strain.

Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States)
Sponsoring Organization:
USDOE
OSTI ID:
1404960
Journal Information:
ACS Medicinal Chemistry Letters, Vol. 7, Issue 12; ISSN 1948-5875
Publisher:
American Chemical Society (ACS)Copyright Statement
Country of Publication:
United States
Language:
ENGLISH
Citation Metrics:
Cited by: 6 works
Citation information provided by
Web of Science

References (16)

Getting Syk: spleen tyrosine kinase as a therapeutic target journal August 2014
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor journal September 2007
Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis journal October 2011
Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy journal January 2013
Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase journal April 2014
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial journal February 2013
The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling journal December 2010
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia journal April 2010
Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis journal September 2005
Inhibition of Spleen Tyrosine Kinase Attenuates Allergen-Mediated Airway Constriction journal December 2013
Overcoming Mutagenicity and Ion Channel Activity: Optimization of Selective Spleen Tyrosine Kinase Inhibitors journal February 2015
A new stereospecific cross-coupling by the palladium-catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynyl halides journal January 1979
Structural Insights for Design of Potent Spleen Tyrosine Kinase Inhibitors from Crystallographic Analysis of Three Inhibitor Complexes journal April 2009
Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor journal August 2011
Discovery and Profiling of a Selective and Efficacious Syk Inhibitor journal February 2015
Using Ovality to Predict Nonmutagenic, Orally Efficacious Pyridazine Amides as Cell Specific Spleen Tyrosine Kinase Inhibitors journal February 2014

Cited By (2)

Indolylboronic Acids: Preparation and Applications journal September 2019
BindingDB Entry 50048032: Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate Optimization. dataset January 2018

Figures / Tables (7)

Figure 1(p. 2)figure Figure 1
Figure 2(p. 3)figure Figure 2
Figure 3(p. 3)figure Figure 3
Figure 4(p. 3)figure Figure 4
Figure 5(p. 4)figure Figure 5
Figure 6(p. 4)figure Figure 6
Table 1(p. 4)table Table 1

Similar Records

Aminopyrazole Carboxamide Bruton’s Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning
Journal Article · Mon Dec 03 00:00:00 EST 2018 · ACS Medicinal Chemistry Letters · OSTI ID:1404960
+29 more
Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events
Journal Article · Sat Mar 15 00:00:00 EDT 2014 · Toxicology and Applied Pharmacology · OSTI ID:1404960
+3 more
A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation
Journal Article · Tue Jan 12 00:00:00 EST 2016 · PLoS ONE · OSTI ID:1404960
+24 more

Related Subjects

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY
60 APPLIED LIFE SCIENCES
Spleen tyrosine kinase
intramolecular hydrogen bond
structure-based drug design
Peptides and proteins
Indoles
Rodent models
Inhibitors
Conformation